
Opinion|Videos|November 15, 2024
Insights from IMS 2024 on Counseling Patients with Multiple Myeloma about CAR T-cell Therapy and Connecting to Referral Centers
Panelists discuss how community providers can implement strategies and utilize resources to effectively connect patients to referral centers for chimeric antigen receptor T-cell therapy, while addressing how to initiate conversations about the therapy and counsel patients regarding potential adverse events.
Advertisement
Episodes in this series

- Dr Ajai Chari to Dr Callander: What are some strategies or potential resources for community providers to connect patients to referral centers?
Resource Link:
- Dr Ajai Chari to Dr Raje: How do you initiate the conversation about chimeric antigen receptor (CAR) T-cell therapy? What do you counsel or share with your patient when explaining CAR T?
Advertisement
Related to this article

Jorge Cortes, MD, discusses response-based ponatinib dosing, mutation testing, and managing cardiovascular risk in resistant CML.

The EC approved every-6-week maintenance dosing and shorter 350-mg infusions for cemiplimab across all 6 EU indications.

Faculty convened at an OncLive Scientific Interchange and Workshop to guide oncology fellows through designing a cancer clinical trial development program, from concept to approval.

The FDA granted priority review to sonesitatug vedotin for previously treated CLDN18.2-positive advanced gastroesophageal cancers.

UCLA Health performs its first single-port robotic lobectomy, using a new technique that could reduce pain and make recovery easier for patients with lung cancer.

Narek Shaverdian, MD, outlines how novel strategies may reshape unresectable stage III NSCLC management.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Sonesitatug Vedotin in CLDN18.2+ Gastroesophageal Cancer
2
Dose Optimization, Evidentiary Bars, and Patient Selection Shape Trial Design in EGFR- and HER2-Mutant NSCLC
3
EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers
4
Defining High-Risk Localized Prostate Cancer and the DASL-HiCaP Trial
5


